Corcept Stock Crashes 50% After FDA Rejection; Securities Fraud Lawsuit Filed

Corcept Therapeutics Incorporated faces a shareholder class action lawsuit following a devastating regulatory setback that wiped roughly half the company's market value in a single trading session. The FDA issued a Complete Response Letter on December 31, 2025, rejecting the company's lead drug candidate relacorilant, contradicting prior investor communications that had emphasized a high probability of approval. The stock plummeted 50.4%, collapsing from $70.20 to $34.80 per share, triggering litigation from investors who claim they were misled about the regulatory pathway and commercial prospects of the company's flagship therapeutic.

The Regulatory Setback and Stock Collapse

The regulatory rejection represents a critical inflection point for Corcept Therapeutics, a biopharmaceutical company whose clinical pipeline centered heavily on relacorilant as its primary growth driver. The FDA's Complete Response Letter, delivered on the final day of 2025, signaled that the agency had significant concerns about the drug candidate's efficacy, safety profile, manufacturing processes, or a combination thereof—concerns the company apparently had not adequately communicated to investors beforehand.

The magnitude of the market reaction underscores the stakes:

• Stock decline: 50.4% single-session drop
• Price action: $70.20 to $34.80 per share
• Approximate market cap destruction: Billions in shareholder value eliminated
• Regulatory outcome: Complete Response Letter (not approval)
• Timeline: FDA decision issued December 31, 2025

Such dramatic single-day collapses following adverse regulatory news are characteristic of biotech companies with concentrated pipelines, where success or failure of a lead candidate often determines the entire investment thesis. Investors who had built positions based on Corcept's prior communications regarding approval likelihood faced instantaneous, catastrophic losses.

The Securities Fraud Claims and Legal Timeline

The class action lawsuit centers on allegations that Corcept Therapeutics made materially misleading or omitted statements regarding the regulatory trajectory of relacorilant. Securities litigation stemming from biotech approvals often hinges on whether companies adequately disclosed known risks, pre-submission meeting outcomes, or FDA feedback that might have suggested approval challenges.

Key legal parameters for affected investors:

• Lead plaintiff deadline: April 21, 2026
• Plaintiff representation: Class action litigation through established securities counsel
• Alleged misconduct period: Prior communications regarding FDA approval likelihood
• Damages basis: Stock price decline from misleading representations

The law firm Kahn Swick & Foti, LLC, through attorney Lewis Kahn, Esq., is accepting inquiries from investors who held Corcept shares and believe they were harmed by the alleged misrepresentations. The April 21, 2026 deadline for lead plaintiff applications establishes a firm cutoff for investors seeking to participate in the litigation or establish standing as representatives of the broader shareholder class.

Market Context and Biotech Sector Implications

The Corcept situation reflects broader fragility in the biotech sector, where binary regulatory outcomes create outsized volatility and where information asymmetries between companies and public shareholders remain significant. Unlike mature pharmaceutical companies with diversified portfolios, clinical-stage and early-revenue biotech firms often depend on a single or handful of pipeline assets to justify their valuations.

Relacorilant represented Corcept's pathway to sustained revenue growth and expanded market opportunities. The drug was being developed for Cushing's syndrome, a rare endocrine disorder characterized by excessive cortisol production. A successful FDA approval would have validated the company's therapeutic approach and positioned Corcept as a meaningful player in endocrine disorder treatments.

The Complete Response Letter suggests that the FDA identified deficiencies that cannot be remedied through minor modifications—these letters typically require substantial additional development work, re-testing, or fundamental reconceptualization of the drug candidate or its manufacturing process. Companies must then decide whether to invest further resources or effectively abandon the program.

Investor protections in the biotech sector remain a persistent challenge:

• Information asymmetry: Companies possess clinical and regulatory data unavailable to shareholders
• Guidance credibility: Forward-looking statements about approval likelihood often rest on subjective interpretation
• Regulatory feedback: Pre-submission meetings with the FDA may contain insights not disclosed to the market
• Pipeline concentration risk: Single-asset companies face existential risks from regulatory failures

Investor Implications and Forward Outlook

For shareholders holding Corcept stock at the time of the FDA decision, the implications are severe. A 50% single-session decline typically reflects a fundamental repricing of the company's enterprise value, with the market essentially recognizing that the primary value driver has been eliminated or substantially diminished.

Broader investor considerations include:

1. Biotech valuation risk: High-growth biotech valuations often embed approval probabilities that may not be transparent or realistic
2. Due diligence gaps: Retail investors often lack access to detailed regulatory intelligence available to institutional players
3. Litigation recovery: Securities class actions in biotech typically recover a modest percentage of shareholder losses, and recovery timelines extend years
4. Sector rotation: The Corcept failure may prompt institutional reassessment of similar clinical-stage biotech exposures

Looking forward, Corcept faces multiple strategic questions: whether to pursue relacorilant development further through alternative regulatory pathways, shift resources to other pipeline assets, or pursue strategic alternatives including asset sales or merger activity. The company's cash position and runway will prove critical to determining which paths remain viable.

For investors evaluating biotech investments, the Corcept case illustrates the importance of independent regulatory analysis, conservative assumptions about approval probabilities, and skepticism toward management guidance when clinical trials approach regulatory decision points. The securities litigation provides a potential avenue for recovering losses, but the lead plaintiff deadline of April 21, 2026 creates an immediate window for affected shareholders to join the class action and establish their claims.